Article
FDA delays decision on BeiGene's cancer drug on China COVID curbs
Rating:
0.0
Views:
50
Likes:
1
Library:
1
China-based drug developer BeiGene said on Thursday the U.S. Food and Drug Administration (FDA) has delayed a decision on its cancer drug as COVID-19 curbs in the country prevented the regulator from conducting inspections.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value